This filing is purely administrative and carries no trading signal. Monitor for the SEC effectiveness notice and final IPO pricing, which will determine the actual market entry point for TARX shares.
Executive Summary
Tarsier Pharma files Amendment No. 3 to its F-1 registration statement solely to add Exhibit 10.10 (a 2016 license agreement for Tuftsin-Phosphorylcholine for ophthalmic indications) and update the exhibit index. No changes were made to the prospectus, offering terms, or financial disclosures. This is a routine administrative filing with no new trading signal.
Key Financial Metrics
Key Facts
- Amendment No. 3 filed June 16, 2026, solely to add Exhibit 10.10 (License Agreement dated January 27, 2016) and update Part II exhibit index.
- Prospectus remains unchanged from the June 8, 2026 filing; no changes to offering size, price range, or use of proceeds.
- Exhibit 10.10 grants Tarsier an exclusive, worldwide, irrevocable, royalty-free license to the Tuftsin-Phosphorylcholine patent portfolio for ophthalmic indications from inventors Yehuda Shoenfeld and Miri Blank.
- The license was originally granted in exchange for 20% of the company's fully diluted share capital upon incorporation.
Financial Impact
No financial impact from this filing; the license agreement was previously disclosed and does not alter the IPO economics.
Risk Factors
- IPO may not be completed if market conditions deteriorate or SEC does not declare the registration statement effective.
- Prior Phase 3 trial of lead candidate TRS01 missed its primary endpoint; new trial design under FDA SPA carries execution risk.
- Company has a history of losses and a going concern risk; post-IPO cash runway depends on successful offering.
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001213900-26-069143 |
| Document: ea027016611ex10-10.htm | 0001213900-26-069143 |
| Document: 0001213900-26-069143-index-headers.html | 0001213900-26-069143 |
| Document: 0001213900-26-069143-index.html | 0001213900-26-069143 |
| Document: 0001213900-26-069143.txt | 0001213900-26-069143 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 16, 2026 18w ago | F-1/A | — | awaiting T+20 | — | — |
Jun 8, 2026 20w ago | F-1/A | — | awaiting T+20 | — | — |
May 18, 2026 23w ago | F-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers